CREBBP and KMT2D mutations frequently come in tandem, maybe owing to an oncogenic cooperation, and this phenomenon was observed in cohorts of the EZB/cluster 3 subset of DLBCL (Table 2). The gene discussed is KMT2D; the disease is diffuse large B-cell lymphoma.